Literature DB >> 8665943

Structure/function analysis of human factor XII using recombinant deletion mutants. Evidence for an additional region involved in the binding to negatively charged surfaces.

F Citarella1, D M Ravon, B Pascucci, A Felici, A Fantoni, C E Hack.   

Abstract

The binding site of human factor XII (FXII) for negatively charged surfaces has been proposed to be localized in the N-terminal region of factor XII. We have generated two recombinant factor XII proteins that lack this region: one protein consisting of the second growth-factor-like domain, the kringle domain, the proline-rich region and the catalytic domain of FXII (rFXII-U-like), and another consisting of only 16 amino acids of the proline-rich region of the heavy-chain region and the catalytic domain (rFXII-1pc). Each recombinant truncated protein, as well as recombinant full-length FXII (rFXII), were produced in HepG2 cells and purified by immunoaffinity chromatography. The capability of these recombinant proteins to bind to negatively charged surfaces and to initiate contact activation was studied. Radiolabeled rFXII-U-like and, to a lesser extent, rFXII-lpc bound to glass in a concentration-dependent manner, yet with lower efficiency than rFXII. The binding of the recombinant proteins was inhibited by a 100-fold molar excess of non-labeled native factor XII. On native polyacrylamide gel electrophoresis, both truncated proteins appeared to bind also to dextran sulfate, a soluble negatively charged compound. Glass-bound rFXII-U-like was able to activate prekallikrein in FXII-deficient plasma (assessed by measuring the generation of kallikrein-C1-inhibitor complexes), but less efficiently than rFXII, rFXII-U-like and rFXII-lpc exhibited coagulant activity, but this activity was significantly lower than that of rFXII. These data confirm that the N-terminal part of the heavy-chain region of factor XII contains a binding site for negatively charged activating surfaces, and indicate that other sequences, possibly located on the second epidermal-growth-factor-like domain and/or the kringle domain, contribute to the binding of factor XII to these surfaces.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8665943     DOI: 10.1111/j.1432-1033.1996.0240q.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  18 in total

1.  Negatively charged silver nanoparticles cause retinal vascular permeability by activating plasma contact system and disrupting adherens junction.

Authors:  Yan-Min Long; Xing-Chen Zhao; Allen C Clermont; Qun-Fang Zhou; Qian Liu; Edward P Feener; Bing Yan; Gui-Bin Jiang
Journal:  Nanotoxicology       Date:  2015-09-23       Impact factor: 5.913

2.  A positively charged cluster in the epidermal growth factor-like domain of Factor VII-activating protease (FSAP) is essential for polyanion binding.

Authors:  Boran Altincicek; Aya Shibamiya; Heidi Trusheim; Eleni Tzima; Michael Niepmann; Dietmar Linder; Klaus T Preissner; Sandip M Kanse
Journal:  Biochem J       Date:  2006-03-15       Impact factor: 3.857

Review 3.  Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis.

Authors:  Evi Stavrou; Alvin H Schmaier
Journal:  Thromb Res       Date:  2010-03       Impact factor: 3.944

4.  Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III.

Authors:  Sven Cichon; Ludovic Martin; Hans Christian Hennies; Felicitas Müller; Karen Van Driessche; Anna Karpushova; Wim Stevens; Roberto Colombo; Thomas Renné; Christian Drouet; Konrad Bork; Markus M Nöthen
Journal:  Am J Hum Genet       Date:  2006-10-18       Impact factor: 11.025

Review 5.  In vivo roles of factor XII.

Authors:  Thomas Renné; Alvin H Schmaier; Katrin F Nickel; Margareta Blombäck; Coen Maas
Journal:  Blood       Date:  2012-09-19       Impact factor: 22.113

Review 6.  Single-chain factor XII: a new form of activated factor XII.

Authors:  Ivan Ivanov; Anton Matafonov; David Gailani
Journal:  Curr Opin Hematol       Date:  2017-09       Impact factor: 3.284

7.  The structure of the FnI-EGF-like tandem domain of coagulation factor XII solved using SIRAS.

Authors:  D X Beringer; L M J Kroon-Batenburg
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2013-01-26

8.  Hereditary angioedema with normal c1 inhibition.

Authors:  Konrad Bork
Journal:  Curr Allergy Asthma Rep       Date:  2009-07       Impact factor: 4.806

9.  Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer.

Authors:  R S Woodruff; Y Xu; J Layzer; W Wu; M L Ogletree; B A Sullenger
Journal:  J Thromb Haemost       Date:  2013-07       Impact factor: 5.824

10.  Contact activation of blood coagulation on a defined kaolin/collagen surface in a microfluidic assay.

Authors:  Shu Zhu; Scott L Diamond
Journal:  Thromb Res       Date:  2014-10-02       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.